Cited by 37Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsIgG4-Related and Inflammatory Diseases

Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody–positive versus antimitochondrial autoantibody–negative primary biliary cirrhosis

Open access
Jin, Qinglong, Moritoki, Yuki, Lleo, Ana, Tsuneyama, Koichi, Invernizzi, Pietro, Moritoki, Hitoshi, Kikuchi, Kentaro, Lian, Zhe-Xiong +5 more·2012·Hepatology

Abstract

Substantial evidence supports dysregulated B-cell immune responses in patients with primary biliary cirrhosis (PBC), including the presence of serum antimitochondrial antibodies (AMAs). However, recent reports from murine models of PBC suggest that B cells may also provide regulatory function, and indeed the absence of B cells in such models leads to exacerbation of disease. The vast majority of patients with PBC have readily detectable AMAs, but a minority (<5%) are AMA negative (AMA−), even with recombinant diagnostic technology. This issue prompted us to examine the nature of B-cell infiltrates surrounding the portal areas in AMA-positive (AMA+) and AMA− patients, because they display indistinguishable clinical features. Of importance was the finding that the degree of bile duct damage around the portal areas was significantly milder in AMA+ PBC than those observed in AMA− PBC patients. The portal areas from AMA− patients had a significant increase of cluster of differentiation (CD)5+ cells infiltrating the ductal regions, and the levels of B-cell infiltrates were worse in the early phase of bile duct damage. The frequency of positive portal areas and the magnitude of CD5+ and CD20+ cellular infiltrates within areas of ductal invasion is associated with the first evidence of damage of biliary duct epithelia, but becomes reduced in the ductopenia stage, with the exception of CD5+ cells, which remain sustained and predominate over CD20+ cells. Conclusion: Our data suggest a putative role of B-cell autoimmunity in regulating the portal destruction characteristic of PBC. (Hepatology 2012)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.25511

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Kaplan MM, Gershwin ME. Medical progress: primary biliary cirrho- sis. N Engl J Med 2005;353:1261-1273.

Cited by

Sorted by citations

Authors
Jin, Q., Moritoki, Y., Lleo, A., Tsuneyama, K., Invernizzi, P., Moritoki, H., Kikuchi, K., Lian, Z.-X., Hirschfield, G. M., Ansari, A. A., Coppel, R. L., Gershwin, E. M., & Niu, J.
Affiliations
  • First Hospital of Jilin University (CN)
  • Akita University (JP)
  • University of Toyama (JP)
  • IRCCS Humanitas Research Hospital (IT)
  • Teikyo University Hospital, Mizonokuchi (JP)
  • University of Science and Technology of China (CN)
  • University of Toronto (CA)
  • Emory University (US)
  • Monash University (AU)
  • University of California, Davis (US)
Corresponding author
Gershwin, Eric M.
Venue
Hepatology
Published
2012-05
Volume
55
Issue
5
Pages
1495-1506
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1977408655
Cited by
37
References
48
Citations by year
2026: 1 · 2025: 1 · 2023: 6 · 2022: 3 · 2021: 2 · 2019: 1 · 2018: 3 · 2017: 4 · 2015: 1 · 2014: 6 · 2013: 5 · 2012: 4
FWCI
3.05
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
Funders
  • National Natural Science Foundation of China (30972610, 200705128, 30771912, 2008ZX10002-004, 20073531)
  • People's Government of Jilin Province
  • National Institutes of Health (DK 39588)
  • Japan Society for the Promotion of Science (21590433, 22890024)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 39588, R37DK039588, R01DK039588)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
Keywords
primary biliary cirrhosis, antimitochondrial antibodies, B-cell infiltrates, CD5+ B cells, CD20+ B cells, bile duct injury, portal inflammation, B cell-mediated autoimmunity, regulatory B cells, ductopenia, biliary epithelium
MeSH terms
Adult, Aged, Autoantibodies, Bile Ducts, Biopsy, Needle, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunohistochemistry, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Liver, Severity of Illness Index, Confidence Intervals, Case-Control Studies, Statistics, Nonparametric, Antigens, CD20, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review